In its latest quarterly filing, Johnson & Johnson revealed that it received a request in June from the U.S. House of Representative’s Committee on Energy and Commerce for records and information pertaining to an investigation into pharmaceutical reimbursements and rebates under Medicaid.
The request focuses on documents for Johnson & Johnson’s Remicade product, marketed through the company’s Centocor, Inc subsidiary.
Johnson & Johnson also said it received a request in July from the U.S. Attorney’s Office, District of New Jersey, to provide documents regarding an investigation into “various Centocor marketing practices.”
Domestic sales for Johnson & Johnson were up 9% to $12.1 billion in the first six fiscal months of 2003.
Network
